A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance
about
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosisPartial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addictionHLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.Sex-dependent treatment of chronic EAE with partial MHC class II constructs.Novel humanized recombinant T cell receptor ligands protect the female brain after experimental strokePreclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic strokeHLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitisEffective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effectsSex differences in the immune response to experimental stroke: Implications for translational research.Predicted structure of MIF/CD74 and RTL1000/CD74 complexesA novel HLA-DRα1-MOG-35-55 construct treats experimental strokeStem cell therapy in autoimmune rheumatic diseases: a comprehensive review.Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Partial MHC class II constructs as novel immunomodulatory therapy for stroke.The challenge of treating orphan disease.Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear CellsMIF and D-DT are potential disease severity modifiers in male MS subjects.DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.
P2860
Q26824619-32492698-3A1E-47FD-81CC-6B652BDFA2B2Q28486981-E20ADDB7-28D9-476C-81B7-00D991F57595Q33641609-5EC131B2-632F-428E-8924-E62BA5599CEFQ33645392-6E8ED6BE-8C7A-4536-B7E6-560962156ADBQ34001070-27BA7375-A4F2-4C63-A126-70AFC27E6096Q34982895-3D33C76D-7AA7-4464-95B6-57DEC7921C46Q35782781-E8776034-D0B8-42BA-BFCA-47801D05BE00Q35946934-48DCEDBC-029F-4260-90E4-D445F295AECDQ37149410-0B984447-4C7B-4667-90DD-F450D220B931Q37202720-B895F1F6-315B-4B2E-9AF4-A17B49FC908FQ37210758-BE3F3362-CFEE-464F-937D-F52DCA0D4FB2Q37432327-1B7AAB6C-7706-4026-AFB8-78BA1BEDCDAEQ37595880-20FD7FE6-4663-482D-A7B2-739BBA838CB0Q37684577-C6316468-5BBF-4AB9-A56E-0C3A7F31AA01Q38242079-506E2FC4-4E33-4880-8D6C-263D58E7C09EQ38477340-4FAC30EA-C907-4430-906E-9C23968CA168Q38743804-327D42CA-96B2-4330-A6BE-9E6B0F2E5904Q38791052-0AAB3901-4E05-41AC-888B-F2B9C8C0C145Q38988985-E086E597-CC67-4B7B-80B2-7F043EF7D51EQ39098238-1E73A410-B892-4379-85DC-B058D2D36BA6Q40400293-F04292F1-8936-4120-A5B6-ECBA08E718B5Q46234913-8562C9DE-FC71-43A1-945F-F0DF956CCE76Q48011437-B4879B66-F181-415E-8447-DAA60ECD14FBQ54941924-CE17584F-7D2F-4543-8A6E-E2EA9972F4BF
P2860
A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel regulatory pathway for ...... and bystander T-cell tolerance
@en
A novel regulatory pathway for ...... nd bystander T-cell tolerance.
@nl
type
label
A novel regulatory pathway for ...... and bystander T-cell tolerance
@en
A novel regulatory pathway for ...... nd bystander T-cell tolerance.
@nl
prefLabel
A novel regulatory pathway for ...... and bystander T-cell tolerance
@en
A novel regulatory pathway for ...... nd bystander T-cell tolerance.
@nl
P2093
P2860
P1476
A novel regulatory pathway for ...... and bystander T-cell tolerance
@en
P2093
Abigail C Buenafe
Arthur A Vandenbark
Gil Benedek
Gregory G Burrows
Halina Offner
Jeffery L Mooney
Jianya Huan
Roberto Meza-Romero
Shayne Andrew
Yoram Reiter
P2860
P304
P356
10.1016/J.JAUT.2012.08.004
P50
P577
2012-09-29T00:00:00Z